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SUMMARY – Transfusion treatment is administered according to clinical and laboratory re-
sults, with ongoing patient assessments. Decisions on necessary measures to prevent any adverse 
and unexpected events and reactions are made on the basis of hemovigilance and ongoing gathering 
and analysis of relevant data. Information about transfusion treatment at the Sestre milosrdnice 
University Hospital Center, Vinogradska site, was retrospectively collected for a period of twelve 
years (2001-2012). In that period, 14137.25±1693.07 units of all blood products were used, where 
red blood cells (RBC) accounted for 67.34%, fresh frozen plasma (FFP) for 17.55%, and platelet 
concentrates (PC) for 14.32%. During the study period, the consumption of RBC was even, of FFP 
decreased by 45% and of PC increased by 58%. RBC transfusions were received by 10.43% of hospi-
talized patients, 1.46% of them during surgical procedures. Transfusions of all blood products were 
received by 14.63% of patients. We found 247 adverse reactions to all blood products. Febrile non-
hemolytic and allergic reactions were quite equally represented, 49.5% each. As for other reactions 
(1%), one transfusion associated circulatory overload and one transfusion related acute lung injury 
were recorded. There were no fatal post-transfusion reactions.
Key words: Blood transfusion – therapy; Blood transfusion – adverse effects; Blood components; Blood 
safety; Maximum surgical blood order schedules
Introduction
New information about the risks of transfusion 
treatment, in particular fear from blood-borne infec-
tious diseases, has encouraged a restrictive approach 
to transfusion treatment. A decision to initiate trans-
fusion treatment is made according to the clinical 
parameters and laboratory results, as well as patient 
assessments. Transfusion treatment needs to be ad-
ministered in a targeted and focused manner and ad-
justed to the specific needs of each patient1.
Patients were not always treated in accordance 
with transfusion treatment guidelines and recommen-
dations, thus being exposed to a greater risk of ad-
verse reactions. According to the literature, 20%-40% 
of red blood cell (RBC) transfusions and 35%-70% of 
fresh frozen plasma (FFP) products were unnecessar-
ily administered2,3. Unjustified RBC transfusions are 
often found in the treatment of mild anemia with no 
clinical signs, in non-hemorrhaging chronic patients, 
and in perioperative transfusion treatment4.
Preoperative anemia is the leading cause of treat-
ment with RBC transfusion5. Mild anemia increases 
postoperative mortality and morbidity rates by ap-
proximately 30%6. Diagnosis and preoperative treat-
ment of anemia according to the cause reduces the 
need of transfusions, duration of treatment, mortal-
ity rates and cost of treatment7. All these procedures 
together constitute the patient blood management 
(PBM) strategy8. In addition to avoiding unneces-
sary transfusions, alternative treatment methods and 
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medicines reducing the need of blood and blood de-
rivatives should be used9. Decisions about the neces-
sary measures to prevent any adverse and unexpected 
events and reactions are made on the basis of hemov-
igilance and ongoing collection and analysis of rel-
evant data10.
Material and Methods
Data were retrospectively collected on transfusion 
treatment at all departments of the Sestre milosrd-
nice University Hospital Center, Vinogradska site, in 
the period from 2001 to 2012. Consumption of blood 
products and the number of post-transfusion reactions 
are presented.
Blood products were dispensed to hospital wards 
on the basis of the Blood and Blood Product Request 
Forms. Such a request form is made in triplicate. It is 
to be signed by the person who collected the patient’s 
blood for pre-transfusion treatment and the physician 
who conducted transfusion treatment. Such a Request 
Form should include the patient’s personal details, di-
agnosis, relevant laboratory results, the blood product 
requested and the number of units.
When a blood product is dispensed, the number of 
units and the time of dispensing should be indicated, 
and the person who conducted the cross-match and 
dispensed the blood product should be signed. The 
third copy of the Request Form is returned from the 
ward to the Department of Transfusion Medicine, to-
gether with the information on the beginning and end 
of transfusion, temperature, blood pressure before and 
after transfusion, and any reactions to the blood prod-
uct. Reporting on the transfusion of each blood prod-
uct and the result of transfusion treatment is part of 
hemovigilance. The patient’s transfusion chart should 
include each dispensed blood product that may be as-
sociated with the donor of units (blood product trace-
ability). Any adverse reactions and alloimmunization 
are recorded in the chart.
Results 
During the study period, 39328±2425 patients per 
year were hospitalized. Every year, 14137.25±1693.07 
units of all blood components were used for transfusion 
treatment, 9452±728.71 RBC units per year, 787.68 
per month and 26 per day. Also, 2486.58±662.04 units 
of FFP were used per year, 207.22 per month and 7 per 
day, and 2075.92±1052.33 units of platelet concentrate 
(PC) per year, 172.99 per month and 5.7 per day. Un-
til 2008, 183.88±167.99 units of whole blood (WB) 
were used per year, 15.32 per month and 0.4 per day, 
after which it was no longer used. The consumption 
of blood products during the study period is shown 
in Figure 1.
Of the total number (14137.25±1693.07) of all 
blood products on annual basis, RBC products ac-
Fig. 1. Consumption of blood products during the study period; WB = whole blood; RBC = red blood cells; PC = platelet 
concentrate; FFP = fresh frozen plasma.
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
445 302 280 305 72 38 27 2 0 0 0 0
9044 9441 9282 10101 10399 10262 7978 9101 8627 9207 10153 9831
2078 2216 1080 1957 1583 1644 1065 1155 1872 2413 4727 3302
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2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Operated 4360 4629 4947 5272 5277 5425 6219 6716 6485 6448 6854 6366
Transfused during 
surgery 545 575 568 449 502 549 571 559 676 682 652 580
Transfused at
all departments 4100 4278 7269 4610 4365 3723 3571 3782 4057 4002 3707 4244
counted for 67.34%, FFP for 17.55% and PC for 
14.32%. The results show even consumption of RBC, 
a drop in the consumption of FFP by approximately 
45%, and an increase in the consumption of PC by 
approximately 58% (Fig. 1).





2001 37584 5975 15.90
2002 35110 6234 17.76
2003 35836 5986 16.70
2004 37187 6171 16.59
2005 38828 5868 15.11
2006 40339 5149 12.76
2007 40320 4859 12.05
2008 42953 5219 12.15
2009 40996 5630 13.73
2010 40031 5791 14.47
2011 41308 5776 13.98
2012 41454 5934 14.31
Table 2. Transfusions of all blood products
According to the relevant preoperative requests for 
ordering and reserving blood units, RBC units were 
prepared for 5577.8±1476.44 patients per year. Trans-
fusion was administered during surgery to 567.6±96.87 
patients a year, or 10.11%±1.49% of all preoperative 
requests (Fig. 2).
During the study period, the number of patients 
that underwent surgical procedure (according to pre-
Year Hospitalized patients RBC %
2001 37584 4100 10.91
2002 35110 4278 12.18
2003 35836 4269 11.91
2004 37187 4610 12.40
2005 38828 4365 11.24
2006 40339 3723 9.23
2007 40320 3571 8.86
2008 42953 3782 8.80
2009 40996 4057 9.90
2010 40031 4002 10.00
2011 41308 3707 8.97
2012 41454 4244 10.24
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Table 3. Incidence of adverse reactions
operative requests for reserving blood doses) increased 
by 46%, while the number of patients that received 
RBC transfusion during surgery decreased by 3%. 
Transfusions of RBC products were administered dur-
ing surgery to 1.46%±0.17% of hospitalized patients 
per year. Transfusions of RBC at all departments of 
the Sestre milosrdnice University Hospital Center 
were administered to 4075±69.3 patients per year, or 
10.43% of hospitalized patients (Table 1).
During the study period, transfusions of all blood 
products (RBC, PC and FFP) were administered to 
5716 patients per year on an average, or 14.63% of hos-
pitalized patients (Table 2).
During the study period, 247 adverse reactions to 
all blood products were reported. Febrile nonhemo-
lytic and allergic reactions were roughly equally rep-
resented (49.5% each). As for other reactions (1%), one 
transfusion associated circulatory overload and one 
transfusion related acute lung injury were recorded. 
There were no fatal post-transfusion reactions.
During the study period, 78.84% of patients expe-
rienced reactions to RBC (46.63% febrile and 32.21% 
allergic), 10.6% experienced reactions to FFP (0.5% 
febrile and 10.1% allergic), 6.74% had reactions to PC 
(1.44% febrile and 5.3% allergic) and 3% to WB (1% 
febrile and 2% allergic). The incidence of all adverse 
post-transfusion reactions per 1000 units of all blood 
products was 7.57‰. Reactions per units were as fol-
lows: WB (4.1‰), RBC (1.77 ‰), FFP (0.87‰), and 
PC (0.83 ‰). The incidence of post-transfusion re-
actions per 1000 hospitalizations was 0.54‰±0.24‰ 
(Table 3, Fig. 3). Reactions per number of patients were 
as follows: RBC 0.43‰, FFP 0.06‰, PC 0.04‰ and 
WB 0.01‰.
The number of post-transfusion reactions reported 
over years decreased from 31 in 2001 to 9 in 2012 
(Table 3, Fig. 3).
Discussion
Transfusion treatment is not equally intensive or 
common in all hospitals and at all hospital departments. 
Anemia is very common in heart, lung, kidney and gas-
trointestinal disease and in malignant tumors. In ma-
lignant hematologic patients, anemia is twice as com-
mon as in patients with solid tumors. A very significant 
cause of anemia in oncologic patients is chemotherapy, 
which additionally increases the need of transfusion 
treatment11. Preoperative anemia is common in patients 
undergoing elective orthopedic surgery (20%-35%), car-
diac surgery (25%-37%) and gastroenterological opera-
tions (>75%), and increases with patient age12,13. Diag-
nosis and preoperative treatment of anemia reduces the 
need of transfusions, length of hospital stay, mortality 
and cost of treatment14. In clinical practice, anemia is 
still very often treated by transfusions, although trans-
fusion treatment should be supportive, short-lasting and 
transient. Good transfusion practice is based on restric-
tive administration of blood and good transfusion prac-
tice does not necessarily imply good clinical practice be-
cause restrictive administration of blood units does not 
















2001 37584 31 0.82
2002 35110 33 0.94
2003 35836 24 0.67
2004 37187 21 0.56
2005 38828 22 0.57
2006 40339 19 0.47
2007 40320 19 0.47
2008 42953 9 0.21
2009 40996 13 0.32
2010 40031 12 0.3
2011 41308 12 0.29
2012 41454 9 0.22
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Etiologic treatments of anemia and coagulopa-
thies prior to hospitalization, reduction of preopera-
tive blood loss (diagnostics), and use of precise sur-
gical and anesthesiologic techniques with restrictive 
transfusion treatment are essential components of 
good clinical practice and good PBM. In practice, 
PBM implies cooperation among different specialists 
involved in the treatment of a patient15.
Analysis of the results for the 12-year study period 
showed even consumption of RBC, a 45% drop in the 
consumption of FFP and a 58% increase in the con-
sumption of PC (Fig. 1). Over years, the consump-
tion of FFP decreased as a result of continuous and 
persistent efforts towards restrictive administration of 
FFP and treatment according to the accepted indica-
tions and guidelines in accordance with global trends. 
These efforts have changed medical practices in FFP 
treatment. The present level of FFP consumption 
for the entire Sestre milosrdnice University Hospital 
Center has been reduced to the consumption level re-
corded at the Intensive Care Unit (ICU) in 1995. The 
ICU alone reduced their FFP consumption 5 times 
from 1995 to 200016.
On the other hand, alternative therapy to FFP is 
available, focusing on compensating only the factor the 
patient lacks (concentrates of coagulation factors and 
prothrombin complex) and causing fewer side effects.
Consumption of ordered and reserved blood prod-
ucts for elective surgical procedures has been moni-
tored at all wards and on all operations. As a result 
of new surgical techniques and restrictive transfusion 
treatment, only 10.11%±1.49% of patients received 
transfusion of reserved RBC products during elec-
tive surgical procedures. During the study period, the 
number of patients that underwent a procedure (ac-
cording to preoperative requests for reserving blood 
units) increased by 46% and the number of patients 
that received transfusion of RBC products decreased 
by 3% (Fig. 2).
Because of all this, each hospital should have its 
own Maximum Surgical Blood Order Schedules (MS-
BOS) program for ordering and reserving blood for 
elective surgeries. This program has been defined by 
experts (surgeons and anesthesiologists) on the basis 
of knowledge and experience and is based on objective 
data on the consumption of blood reserved for each 
operation. In this way, an optimal number of blood 
product units are ordered for each surgical procedure, 
patient safety is enhanced, and the cost of treatment is 
reduced17. MSBOS is planned for elective operations 
according to the average consumption of RBC prod-
ucts for each operation, including the clinical condi-
tion of each patient. Each patient and each operation 
is different and a single transfusion treatment is not 
applicable to all patients. The recommended ratio be-
tween the ordered and reserved blood products for 
intraoperative patient transfusion is 2:1. Such a blood 
consumption ratio indicates good management of 
transfusion treatment and blood inventories.
There are no common side effects of transfusion 
treatment. If they do occur, they may affect patient 
morbidity and mortality, length of hospital stay and 
cost of treatment. The number of post-transfusion 
reactions reported over years decreased for several 
reasons. WB has not been used since 2008 and RBC 
have been used since 2004 without a leukocyte and 
platelet layer (RBC products with reduced leukocyte 
count in nutrient solution, filtered). These changes 
have significantly improved the quality of blood prod-
ucts8 and this is why the number of febrile and allergic 
reactions to RBC products has decreased.
During the 12-year study period, the number of 
FFP units decreased by 45%, so the number of allergic 
reactions to these products also decreased as expected. 
In addition, it is highly likely that mild post-trans-
fusion reactions were not reported, identified and/or 
associated with transfusion treatment.
The quality of transfusion treatment is assessed ac-
cording to its success and safety, identification of the 
risk of adverse reactions, their seriousness and associa-
tion with transfusion treatment.
Conclusion
Clinical and economic indicators recommend re-
strictive administration of blood and good transfusion 
treatment management. The implementation of Euro-
pean and national hemovigilance and PBM programs 
promotes the culture of transfusion treatment. Namely, 
each unjustified transfusion is considered to be a human 
error. By incorporating it in the national e-Delphyn 
information system, all information about transfusion 
treatment of patients in the Republic of Croatia have 
been transparent and easily available as of 2013.
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Sažetak
TRANSFUZIJSKO LIJEČENJE U KBC SESTRE MILOSRDNICE TIJEKOM DVANAEST GODINA
D. Sović, J. Dodig, M. Banović i A. Jularić
Transfuzijsko liječenje se provodi prema kliničkim i laboratorijskim nalazima uz stalnu procjenu bolesnikova sta-
nja. Nadzorom transfuzijskog liječenja (hemovigilancija) uz kontinuirano prikupljanje i analizu podataka o neželjenim 
i neočekivanim događajima i reakcijama prosuđuje se o potrebnim mjerama kojima bi se oni spriječili. Retrogradno su 
prikupljeni podaci o transfuzijskom liječenju bolesnika u KBC Sestre milosrdnice, lokacija Vinogradska, tijekom dvanaest 
godina (2001.-2012.). Potrošeno je godišnje 14137,25±1693,07 doza svih krvnih pripravaka. Udio eritrokoncentrata (KE) 
bio je 67,34%, svježe smrznute plazme (SSP) 17,55% i trombokoncentrata (KT) 14,32%. Tijekom promatranog razdoblja 
potrošnja KE bila je ujednačena, SSP smanjena za 45% i KT povećana za 58%. Transfuzije KE je primilo 10,43% hospitali-
ziranih bolesnika. Tijekom kirurških zahvata transfuzije KE je primilo 10,11% bolesnika, odnosno 1,46% hospitaliziranih 
bolesnika. Transfuzije svih krvnih pripravaka primilo je 14,63% bolesnika. U promatranom razdoblju prijavljeno je 247 
poslijetransfuzijskih reakcija na sve krvne pripravke. U zbroju svih reakcija podjednako su zastupljene febrilne nehemo-
litičke i alergijske reakcije (49,5%). Od ostalih (1%) jedna je bila preopterećenje kardiovaskularnog sustava i jedna akutna 
plućna insuficijencija uzrokovana transfuzijom. Nije bilo poslijetransfuzijskih reakcija sa smrtnim ishodom.
Ključne riječi: Transfuzija krvi – terapija; Transfuzija krvi – štetni učinci; Krvni pripravci; Sigurnost; Shema naručivanja 
količine krvi za operaciju
